论文部分内容阅读
目的:观察健脾中药延长结直肠癌肝转移患者生存期的作用。方法:采用前瞻性、随机、对照的临床流行病学方法,将符合标准的病例按中药加化疗和化疗两组治疗。结果:化疗组的中位生存时间为548天,1年生存率为67.8%,3年生存率为15.3%;中药加化疗组的中位生存时间为756天,1年生存率为82.9%,3年生存率为11.90%。结论:虽然由于样本量较少,没有显示出统计学差异,但加入健脾中药的化疗病人仍显示出了生存期延长的趋势。
Objective: To observe the effect of spleen and herbs on prolonging the survival of patients with liver metastases from colorectal cancer. Methods: A prospective, randomized, controlled clinical epidemiological approach was used to treat patients who met the criteria according to Chinese medicine plus chemotherapy and chemotherapy. Results: The median survival time of the chemotherapy group was 548 days. The 1-year survival rate was 67.8% and the 3-year survival rate was 15.3%. The median survival time of the traditional Chinese medicine plus chemotherapy group was 756 days, and the 1-year survival rate was 82.9% 3-year survival rate was 11.90%. Conclusion: Although there was no statistical difference due to the small sample size, the chemotherapy patients who were treated with Chinese herbal medicine of spleen still showed a prolonged survival trend.